.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,962,314

« Back to Dashboard

Details for Patent: 5,962,314

Title: Calcium receptor-active molecules
Abstract:The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
Inventor(s): Brown; Edward M. (Milton, MA), Hebert; Steven C. (Wellesley, MA), Garrett, Jr.; James E. (Salt Lake City, UT)
Assignee: NPS Pharmaceuticals, Inc. (Salt Lake City, UT) Brigham and Women's Hospital (Boston, MA)
Filing Date:Oct 03, 1997
Application Number:08/943,986
Claims:1. An expression vector comprising at least 20 contiguous nucleotides of a nucleic acid sequence from nucleotide 515 to 3769 of SEQ ID NO: 1.

2. An expression vector comprising at least 27 contiguous nucleotides of a nucleic acid sequence from nucleotide 515 to 3769 of SEQ ID NO: 1.

3. An expression vector comprising at least 45 contiguous nucleotides of a nucleic acid sequence from nucleotide 515 to 3769 of SEQ ID NO: 1.

4. An expression vector comprising a nucleic acid sequence selected from the group consisting of: nucleotides 515 to 3769 of SEQ ID NO: 1, nucleotides 436 to 3699 of SEQ ID NO: 2, nucleotides 373 to 3606 of SEQ ID NO: 3 and nucleotides 574 to 3810 of SEQ ID NO: 4.

5. The expression vector of claim 4, wherein said nucleic acid sequence is SEQ ID NO: 1.

6. The expression vector of claim 4, wherein said nucleic acid sequence is SEQ ID NO: 2.

7. The expression vector of claim 4, wherein said nucleic acid sequence is SEQ ID NO: 3.

8. The expression vector of claim 4, wherein said nucleic acid sequence is SEQ ID NO: 4.

9. An expression vector comprising a nucleic acid sequence encoding at least 12 contiguous amino acids of an amino acid sequence provided in SEQ ID NO: 5.

10. An expression vector comprising a nucleic acid sequence encoding at least 18 contiguous amino acids of an amino acid sequence provided in SEQ ID NO: 5.

11. An expression vector comprising a nucleic acid sequence encoding at least 54 contiguous amino acids of an amino acid sequence provided in SEQ ID NO: 5.

12. An expression vector comprising a nucleic acid sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8.

13. The expression vector of claim 12, wherein said amino acid sequence is SEQ ID NO: 5.

14. The expression vector of claim 12, wherein said amino acid sequence is SEQ ID NO: 6.

15. The expression vector of claim 12, wherein said amino acid sequence is SEQ ID NO: 7.

16. The expression vector of claim 12, wherein said amino acid sequence is SEQ ID NO: 8.

17. A recombinant cell comprising the expression vector of any one of claims 1-16.

18. A recombinant cell made by a process comprising the step of introducing the expression vector of any one of claims 1-16 into the cell.

19. A recombinant nucleic acid comprising at least 20 contiguous nucleotides of a sequence from nucleotide 515 to 3769 of SEQ ID NO: 1, transcriptionally coupled to an exogenous promoter.

20. A recombinant nucleic acid comprising at least 27 contiguous nucleotides of a sequence from nucleotide 515 to 3769 of SEQ ID NO: 1, transcriptionally coupled to an exogenous promoter.

21. A recombinant nucleic acid comprising at least 45 contiguous nucleotides of a sequence from nucleotide 515 to 3769 of SEQ ID NO: 1, transcriptionally coupled to an exogenous promoter.

22. A recombinant nucleic acid comprising a nucleic acid sequence selected from the group consisting of: nucleotides 515 to 3769 of SEQ ID NO: 1, nucleotides 436 to 3699 of SEQ ID NO: 2, nucleotides 373 to 3606 of SEQ ID NO: 3 and nucleotides 574 to 3810 of SEQ ID NO: 4, wherein said nucleic acid sequence is transcriptionally coupled to an exogenous promoter.

23. The recombinant nucleic acid of claim 22, wherein said nucleic acid sequence is SEQ ID NO: 1.

24. The recombinant nucleic acid of claim 22, wherein said nucleic acid sequence is SEQ ID NO: 2.

25. The recombinant nucleic acid of claim 22, wherein said nucleic acid sequence is SEQ ID NO: 3.

26. The recombinant nucleic acid of claim 22, wherein said nucleic acid sequence is SEQ ID NO: 4.

27. A recombinant nucleic acid comprising a nucleic acid sequence encoding at least 12 contiguous amino acids of an amino acid sequence provided in SEQ ID NO: 5, wherein said nucleic acid sequence is trancriptionally coupled to an exogenous promoter.

28. A recombinant nucleic acid comprising a nucleic acid sequence encoding at least 18 contiguous amino acids of an amino acid sequence provided in SEQ ID NO: 5, wherein said nucleic acid sequence is transcriptionally coupled to an exogenous promoter.

29. A recombinant nucleic acid comprising a nucleic acid sequence encoding at least 54 contiguous amino acids of an amino acid sequence provided in SEQ ID NO: 5, wherein said nucleic acid sequence is transcriptionally coupled to an exogenous promoter.

30. A recombinant nucleic acid comprising a nucleic acid sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, wherein said nucleic acid sequence is transcriptionally coupled to an exogenous promoter.

31. The recombinant nucleic acid of claim 30, wherein said amino acid sequence is SEQ ID NO: 5.

32. The recombinant nucleic acid of claim 30, wherein said amino acid sequence is SEQ ID NO: 6.

33. The recombinant nucleic acid of claim 30, wherein said amino acid sequence is SEQ ID NO: 7.

34. The recombinant nucleic acid of claim 3, wherein said amino acid sequence is SEQ ID NO: 8.

35. A recombinant cell comprising the recombinant nucleic acid of any one of claims 19-34.

36. A recombinant cell made by a process comprising the step of introducing the recombinant nucleic acid of any one of claims 19-34 into the cell.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc